Cargando…
HER2 Expression Associated with Clinical Characteristics and Prognosis of Urothelial Carcinoma in a Chinese Population
BACKGROUND: The frequency of HER2 overexpression in bladder cancer is reported as 9%-61%. HER2 alteration correlates with aggressive disease in bladder cancer. Traditional anti-HER2 targeted therapy has failed to show clinical benefits in patients with advanced urothelial carcinoma . METHODS: The in...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10400138/ https://www.ncbi.nlm.nih.gov/pubmed/36971495 http://dx.doi.org/10.1093/oncolo/oyad070 |
_version_ | 1785084399235104768 |
---|---|
author | Zhou, Li Shao, Zhiting Liu, Yiqiang Yan, Xieqiao Li, Juan Wu, Xiaowen Tang, Bixia Li, Siming Cui, Chuanliang Chi, Zhihong Si, Lu Kong, Yan Mao, Lili Lian, Bin Wang, Xuan Bai, Xue Dai, Jie Guo, Jun Sheng, Xinan |
author_facet | Zhou, Li Shao, Zhiting Liu, Yiqiang Yan, Xieqiao Li, Juan Wu, Xiaowen Tang, Bixia Li, Siming Cui, Chuanliang Chi, Zhihong Si, Lu Kong, Yan Mao, Lili Lian, Bin Wang, Xuan Bai, Xue Dai, Jie Guo, Jun Sheng, Xinan |
author_sort | Zhou, Li |
collection | PubMed |
description | BACKGROUND: The frequency of HER2 overexpression in bladder cancer is reported as 9%-61%. HER2 alteration correlates with aggressive disease in bladder cancer. Traditional anti-HER2 targeted therapy has failed to show clinical benefits in patients with advanced urothelial carcinoma . METHODS: The information on pathologically proven patients with urothelial carcinoma with detected HER2 status was collected from the database of Peking University Cancer Hospital. The HER2 expression, as well as its association with clinical characteristics and prognosis, was analyzed. RESULTS: A total of 284 consecutive patients with urothelial carcinoma were enrolled. HER2 was positive (IHC 2+/3+) in 44% of urothelial carcinoma. HER2 positivity was found more frequent in UCB than in UTUC (51% vs. 38%). Stage, radical surgery, and histological variant were associated with survival (P < .05). For metastatic patients, multivariate analysis shows that 3 indicators, including liver metastasis, the number of involved organs, and anemia, are independent risk factors of prognosis. Receiving immunotherapy or disitamab vedotin (DV) treatment is an independent protecting factor. The survival of patients with low HER2 expression was also significantly improved by the treatment of DV (P < .001). HER2 expression (IHC 1+, 2+, 3+) was associated with a better prognosis in this population. CONCLUSION: DV has improved the survival of patients with urothelial carcinoma in the real world. With the new-generation anti-HER2 ADC treatment, HER2 expression is no longer a poor prognostic factor. |
format | Online Article Text |
id | pubmed-10400138 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-104001382023-08-04 HER2 Expression Associated with Clinical Characteristics and Prognosis of Urothelial Carcinoma in a Chinese Population Zhou, Li Shao, Zhiting Liu, Yiqiang Yan, Xieqiao Li, Juan Wu, Xiaowen Tang, Bixia Li, Siming Cui, Chuanliang Chi, Zhihong Si, Lu Kong, Yan Mao, Lili Lian, Bin Wang, Xuan Bai, Xue Dai, Jie Guo, Jun Sheng, Xinan Oncologist Genitourinary Cancer BACKGROUND: The frequency of HER2 overexpression in bladder cancer is reported as 9%-61%. HER2 alteration correlates with aggressive disease in bladder cancer. Traditional anti-HER2 targeted therapy has failed to show clinical benefits in patients with advanced urothelial carcinoma . METHODS: The information on pathologically proven patients with urothelial carcinoma with detected HER2 status was collected from the database of Peking University Cancer Hospital. The HER2 expression, as well as its association with clinical characteristics and prognosis, was analyzed. RESULTS: A total of 284 consecutive patients with urothelial carcinoma were enrolled. HER2 was positive (IHC 2+/3+) in 44% of urothelial carcinoma. HER2 positivity was found more frequent in UCB than in UTUC (51% vs. 38%). Stage, radical surgery, and histological variant were associated with survival (P < .05). For metastatic patients, multivariate analysis shows that 3 indicators, including liver metastasis, the number of involved organs, and anemia, are independent risk factors of prognosis. Receiving immunotherapy or disitamab vedotin (DV) treatment is an independent protecting factor. The survival of patients with low HER2 expression was also significantly improved by the treatment of DV (P < .001). HER2 expression (IHC 1+, 2+, 3+) was associated with a better prognosis in this population. CONCLUSION: DV has improved the survival of patients with urothelial carcinoma in the real world. With the new-generation anti-HER2 ADC treatment, HER2 expression is no longer a poor prognostic factor. Oxford University Press 2023-03-27 /pmc/articles/PMC10400138/ /pubmed/36971495 http://dx.doi.org/10.1093/oncolo/oyad070 Text en © The Author(s) 2023. Published by Oxford University Press. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com. |
spellingShingle | Genitourinary Cancer Zhou, Li Shao, Zhiting Liu, Yiqiang Yan, Xieqiao Li, Juan Wu, Xiaowen Tang, Bixia Li, Siming Cui, Chuanliang Chi, Zhihong Si, Lu Kong, Yan Mao, Lili Lian, Bin Wang, Xuan Bai, Xue Dai, Jie Guo, Jun Sheng, Xinan HER2 Expression Associated with Clinical Characteristics and Prognosis of Urothelial Carcinoma in a Chinese Population |
title | HER2 Expression Associated with Clinical Characteristics and Prognosis of Urothelial Carcinoma in a Chinese Population |
title_full | HER2 Expression Associated with Clinical Characteristics and Prognosis of Urothelial Carcinoma in a Chinese Population |
title_fullStr | HER2 Expression Associated with Clinical Characteristics and Prognosis of Urothelial Carcinoma in a Chinese Population |
title_full_unstemmed | HER2 Expression Associated with Clinical Characteristics and Prognosis of Urothelial Carcinoma in a Chinese Population |
title_short | HER2 Expression Associated with Clinical Characteristics and Prognosis of Urothelial Carcinoma in a Chinese Population |
title_sort | her2 expression associated with clinical characteristics and prognosis of urothelial carcinoma in a chinese population |
topic | Genitourinary Cancer |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10400138/ https://www.ncbi.nlm.nih.gov/pubmed/36971495 http://dx.doi.org/10.1093/oncolo/oyad070 |
work_keys_str_mv | AT zhouli her2expressionassociatedwithclinicalcharacteristicsandprognosisofurothelialcarcinomainachinesepopulation AT shaozhiting her2expressionassociatedwithclinicalcharacteristicsandprognosisofurothelialcarcinomainachinesepopulation AT liuyiqiang her2expressionassociatedwithclinicalcharacteristicsandprognosisofurothelialcarcinomainachinesepopulation AT yanxieqiao her2expressionassociatedwithclinicalcharacteristicsandprognosisofurothelialcarcinomainachinesepopulation AT lijuan her2expressionassociatedwithclinicalcharacteristicsandprognosisofurothelialcarcinomainachinesepopulation AT wuxiaowen her2expressionassociatedwithclinicalcharacteristicsandprognosisofurothelialcarcinomainachinesepopulation AT tangbixia her2expressionassociatedwithclinicalcharacteristicsandprognosisofurothelialcarcinomainachinesepopulation AT lisiming her2expressionassociatedwithclinicalcharacteristicsandprognosisofurothelialcarcinomainachinesepopulation AT cuichuanliang her2expressionassociatedwithclinicalcharacteristicsandprognosisofurothelialcarcinomainachinesepopulation AT chizhihong her2expressionassociatedwithclinicalcharacteristicsandprognosisofurothelialcarcinomainachinesepopulation AT silu her2expressionassociatedwithclinicalcharacteristicsandprognosisofurothelialcarcinomainachinesepopulation AT kongyan her2expressionassociatedwithclinicalcharacteristicsandprognosisofurothelialcarcinomainachinesepopulation AT maolili her2expressionassociatedwithclinicalcharacteristicsandprognosisofurothelialcarcinomainachinesepopulation AT lianbin her2expressionassociatedwithclinicalcharacteristicsandprognosisofurothelialcarcinomainachinesepopulation AT wangxuan her2expressionassociatedwithclinicalcharacteristicsandprognosisofurothelialcarcinomainachinesepopulation AT baixue her2expressionassociatedwithclinicalcharacteristicsandprognosisofurothelialcarcinomainachinesepopulation AT daijie her2expressionassociatedwithclinicalcharacteristicsandprognosisofurothelialcarcinomainachinesepopulation AT guojun her2expressionassociatedwithclinicalcharacteristicsandprognosisofurothelialcarcinomainachinesepopulation AT shengxinan her2expressionassociatedwithclinicalcharacteristicsandprognosisofurothelialcarcinomainachinesepopulation |